Background:Cisplatin-radiotherapy is a preferred standard for locally advanced, head and neck squamous cell carcinoma (HNSCC). However, the cisplatin-attributable survival benefit is small and toxicity substantial. A biomarker of cisplatin resistance could guide treatment selection and spare morbidity. The ERCC1-XPF nuclease is critical to DNA repair pathways resolving cisplatin-induced lesions.Methods:In a phase II trial, patients with untreated Stage III-IVb HNSCC were randomised to cisplatin-radiotherapy with/without erlotinib. Archived primary tumours were available from 90 of 204 patients for this planned substudy. Semi-quantitative ERCC1 protein expression (H-score) was determined using the FL297, 4F9, and 8F1 antibodies. The primary ...
Background: Induction chemotherapy is a common therapeutic option for patients with locoregionally-a...
Full list of author information is available at the end of the articleBackground The current standar...
Background: Platinum-based therapy, combined or not with immune checkpoint inhibitors, represents a ...
Background:Cisplatin-radiotherapy is a preferred standard for locally advanced, head and neck squamo...
The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the n...
Excision repair cross-complementation group 1 (ERCC1) protein has been extensively investigated as a...
Poster Highlights Session - Head and Neck Cancer: abstract no. 6029Background: Polymorphisms at ERC...
Adjuvant cisplatin-based chemoradiation improves survival in HNSCC patients presenting with risk fea...
IntroductionThe relationship between excision repair cross-complementation group 1 (ERCC1) expressio...
Identifying patients with locally advanced head and neck carcinoma on high risk of recurrence after ...
Purpose Retrospective studies indicate that expression of excision repair cross complementing group ...
Abstract Background This study was to evaluate the effect of excision repair cross-complementation g...
Identifying patients with locally advanced head and neck carcinoma on high risk of recurrence after ...
Platinum-based drugs form a key aspect of multimodal treatment to various cancers. Despite this, res...
Purpose Retrospective studies indicate that expression of excision repair cross complementing group ...
Background: Induction chemotherapy is a common therapeutic option for patients with locoregionally-a...
Full list of author information is available at the end of the articleBackground The current standar...
Background: Platinum-based therapy, combined or not with immune checkpoint inhibitors, represents a ...
Background:Cisplatin-radiotherapy is a preferred standard for locally advanced, head and neck squamo...
The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the n...
Excision repair cross-complementation group 1 (ERCC1) protein has been extensively investigated as a...
Poster Highlights Session - Head and Neck Cancer: abstract no. 6029Background: Polymorphisms at ERC...
Adjuvant cisplatin-based chemoradiation improves survival in HNSCC patients presenting with risk fea...
IntroductionThe relationship between excision repair cross-complementation group 1 (ERCC1) expressio...
Identifying patients with locally advanced head and neck carcinoma on high risk of recurrence after ...
Purpose Retrospective studies indicate that expression of excision repair cross complementing group ...
Abstract Background This study was to evaluate the effect of excision repair cross-complementation g...
Identifying patients with locally advanced head and neck carcinoma on high risk of recurrence after ...
Platinum-based drugs form a key aspect of multimodal treatment to various cancers. Despite this, res...
Purpose Retrospective studies indicate that expression of excision repair cross complementing group ...
Background: Induction chemotherapy is a common therapeutic option for patients with locoregionally-a...
Full list of author information is available at the end of the articleBackground The current standar...
Background: Platinum-based therapy, combined or not with immune checkpoint inhibitors, represents a ...